canertinib has been researched along with cudc 101 in 2 studies
| Studies (canertinib) | Trials (canertinib) | Recent Studies (post-2010) (canertinib) | Studies (cudc 101) | Trials (cudc 101) | Recent Studies (post-2010) (cudc 101) |
|---|---|---|---|---|---|
| 124 | 9 | 65 | 39 | 2 | 35 |
| Protein | Taxonomy | canertinib (IC50) | cudc 101 (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 0.1561 | |
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 2.89 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.0046 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0525 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 5.91 | |
| Tyrosine-protein kinase Lyn | Homo sapiens (human) | 0.84 | |
| Proto-oncogene tyrosine-protein kinase receptor Ret | Homo sapiens (human) | 3.2 | |
| Fibroblast growth factor receptor 2 | Homo sapiens (human) | 3.43 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.849 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 1.5 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.1567 | |
| Fatty-acid amide hydrolase 1 | Rattus norvegicus (Norway rat) | 3.7086 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.1554 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.2081 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.1566 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.1815 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.1806 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.1662 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.1555 | |
| Histone deacetylase 9 | Homo sapiens (human) | 0.1644 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.1564 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
2 other study(ies) available for canertinib and cudc 101
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |